Publications by authors named "A Kherlopian"
We report a rare case of a pedunculated calcified amorphous tumor (CAT) of the left ventricle attached by a stalk to the membranous septum in a 74-year-old woman who presented with a cerebrovascular accident. We believe this is the first report of a CAT attached to the membranous septum.
View Article and Find Full Text PDFBackground: Aortic stenosis (AS) is the most common degenerative valve disease in high income countries. While hemodynamic metrics are commonly used to assess severity of stenosis, they are impacted by loading conditions and stroke volume and are often discordant. Anatomic valve assessments such as aortic valve calcification (AVC) and valve motion (VM) during transthoracic echocardiography (TTE) can offer clues to disease severity.
View Article and Find Full Text PDFObjectives: Some practitioners are adopting proactive topical corticosteroid (TCS) therapy for vulval lichen sclerosus (VLS). We sought to understand patient attitudes toward proactive TCS therapy for VLS in a context in which proactive therapy is adopted.
Methods: Four online focus group discussions with 12 participants.
Background/objectives: For patients with vulvovaginal lichen planus (VLP), there exists limited data on the comparison between patient quality of life treated with topical and/or systemic treatments. We characterised the treatment outcomes of VLP using the vulvar quality of life index (VQLI) comparing women treated with systemic immunosuppression, including humanised interleukin-23 monoclonal antibody tildrakizumab, to those treated with topical corticosteroids alone.
Methods: A retrospective cohort study is reported from a dermatology practice in Sydney, Australia.
Article Synopsis
- Toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome are severe skin reactions that require urgent medical care, with no established treatment protocols.
- A study reviewed patients with TEN from 2017 to 2021, comparing those treated with the TNF-α inhibitor adalimumab to those on other immunosuppressive therapies.
- Results showed that adalimumab led to faster recovery, with patients hospitalized for an average of 22.5 days versus 33 days for those on non-TNF-α drugs, indicating its potential as an effective treatment option.